Chemours Company (The)

As of June 30, 2026, Chemours Co. carries a market capitalization of 2.55B, placing it among publicly traded companies globally. Its enterprise value stands at 5.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chemours Co.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Chemours Co. has 150.34M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.55, and the price-to-book ratio stands at -64.47.

As of June 30, 2026, Chemours Co. trades at an EV/EBITDA multiple of 13.83 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 41.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.34B versus a market cap of 2.55B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chemours Co. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -8,583.33, indicating conservative leverage, while an interest coverage ratio of 1.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -4.15, reflecting losses generated across the asset base. The company generates approximately 810,907.45 in revenue per employee across its workforce of 5,775.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.26 indicates how many times Chemours Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chemours Co. recorded 214.88M in income tax expense. The company reported a pretax loss of -31.51M and -245.58M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on June 29, 2026, Chemours Co.'s stock has gained approximately 83.93% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Chemours Co. generated 4.68B in revenue and converted that into -245.58M in net income, yielding earnings per share of -1.63. EBITDA reached 386.14M, while operating income came in at -67.05M.

As of June 30, 2026, Chemours Co. holds 542.05M in cash and equivalents against 3.33B in total debt, resulting in a net debt position of 2.59B. Total book value stands at -39.58M, with working capital of 996.05M providing operational flexibility.

Chemours Co. produced 320.71M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -144.60M in capital expenditures, free cash flow totaled 176.11M - equivalent to 1.17 per share.

Over the twelve months ended June 30, 2026, Chemours Co. posted a gross margin of 15.30, reflecting its pricing power and cost economics. The operating margin of -1.43 and net profit margin of -5.24 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chemours Co. paid dividends of 0.29 per share. The dividend payout ratio of -17.65 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.86, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 11.08, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chemours Co. shareholders.

As of June 30, 2026, Chemours Co. has an Altman Z-Score of 1.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.